OR YEHUDA, ISRAEL--(Marketwire - May 11, 2011) - P-Cure has expanded its operations by opening a U.S. office in Chicago, IL and adding an experienced medical device executive, Israel Raz, to its leadership team in the role of Chief Operating Officer. P-Cure's innovative approach to proton therapy offers significant clinical, economic and operational benefits that facilitate the adoption of this treatment for routine clinical practice.
"It is important at this point in our development to establish operations in the United States to drive our growth in the Americas and other international markets," said Michael Marash, PhD, Founder and CEO of P‐Cure Ltd. "We are very fortunate to have Israel Raz on board to spearhead and lead these efforts. His expertise and accomplishments in developing new markets for innovative medical devices make him a valuable addition to our team."
Mr. Raz joins P-Cure from Given Imaging, where he served as Senior VP, Chief Marketing Officer. He has more than 20 years of experience in strategic marketing, business development, and global commercialization of innovative medical devices in a wide variety of imaging technologies and medical specialties, and with companies ranging from a startup venture to GE Healthcare, where he served as the GM Global Marketing for Molecular Imaging. His industry tenure was preceded by academic research and teaching.
"I am delighted to join a company of P-Cure's quality, and look forward to bringing the unique value offered by P-Cure to customers in the U.S. and around the world," Mr. Raz said. "P-Cure is shifting the paradigm for proton therapy treatment, and it's exciting to be a part of a development that offers a clear clinical benefit to so many people. The U.S. base lets us be close to the customers and best address their evolving needs."
About P-Cure
P‐Cure develops advanced solutions that help bring proton therapy to routine clinical practice. The P-Cure system provides an integrated solution with volumetric imaging, patient immobilization and positioning, and treatment plan adaptation capabilities. The company's P-ART™ patient positioning software system received FDA 510(k) clearance. For additional information, visit www.p-cure.com.
Israel: P-Cure Ltd. | 3A Yoni Netanyahu St. | Or Yehuda 60376 | Israel | +972 (3) 533-0130
US: P-Cure Inc. | 500 Lake Cook Rd. | Suite 350 |Deerfield, IL 60015 | +1 (847) 874-7771
info@p-cure.com | www.p-cure.com
Contact Information:
Media Contact:
Lynn Hood
678-974-2623